279 related articles for article (PubMed ID: 16620147)
41. Ranolazine and other antianginal therapies in the era of the drug-eluting stent.
Berger P
JAMA; 2004 Jan; 291(3):365-7. PubMed ID: 14734600
[No Abstract] [Full Text] [Related]
42. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.
Antzelevitch C; Belardinelli L; Wu L; Fraser H; Zygmunt AC; Burashnikov A; Di Diego JM; Fish JM; Cordeiro JM; Goodrow RJ; Scornik F; Perez G
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S65-83. PubMed ID: 15378132
[TBL] [Abstract][Full Text] [Related]
43. Ranolazine: clinical applications and therapeutic basis.
Hawwa N; Menon V
Am J Cardiovasc Drugs; 2013 Feb; 13(1):5-16. PubMed ID: 23335347
[TBL] [Abstract][Full Text] [Related]
44. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
Maier LS
J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of ranolazine in patients with chronic stable angina.
Kloner RA; Hines ME; Geunes-Boyer S
Postgrad Med; 2013 Nov; 125(6):43-52. PubMed ID: 24200760
[TBL] [Abstract][Full Text] [Related]
46. Ranolazine: a new option in the management of chronic stable angina.
Dobesh PP; Trujillo TC
Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887
[TBL] [Abstract][Full Text] [Related]
47. Ranolazine: a new approach to treating an old problem.
Reddy BM; Weintraub HS; Schwartzbard AZ
Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
[TBL] [Abstract][Full Text] [Related]
48. Ranolazine as add-on therapy for patients with severe chronic angina.
Hooper JS; Busti AJ
JAMA; 2004 Apr; 291(16):1959; author reply 1959-60. PubMed ID: 15113810
[No Abstract] [Full Text] [Related]
49. Trials and tribulations associated with angina and traditional therapeutic approaches.
Deedwania PC; Carbajal EV; Bobba VR
Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I16-24. PubMed ID: 18373326
[TBL] [Abstract][Full Text] [Related]
50. Ranolazine: focusing on angina pectoris.
McCullough PA
Drugs Today (Barc); 2006 Mar; 42(3):177-83. PubMed ID: 16628259
[TBL] [Abstract][Full Text] [Related]
51. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.
Savarese G; Rosano G; D'Amore C; Musella F; Della Ratta GL; Pellegrino AM; Formisano T; Vitagliano A; Cirillo A; Cice G; Fimiani L; del Guercio L; Trimarco B; Perrone-Filardi P
Int J Cardiol; 2013 Nov; 169(4):262-70. PubMed ID: 24063912
[TBL] [Abstract][Full Text] [Related]
52. Ranolazine: an antianginal drug with antiarrhythmic properties.
Tamargo J; Caballero R; Delpón E
Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
[TBL] [Abstract][Full Text] [Related]
54. [Ranolazine--new treatment of chronic stable angina pectoris].
Ahlehoff O; Hansen PR
Ugeskr Laeger; 2009 Dec; 171(50):3705-7. PubMed ID: 20003868
[TBL] [Abstract][Full Text] [Related]
55. Clinical experience with ranolazine in a veteran population with chronic stable angina.
Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
[TBL] [Abstract][Full Text] [Related]
56. Update on ranolazine in the management of angina.
Codolosa JN; Acharjee S; Figueredo VM
Vasc Health Risk Manag; 2014; 10():353-62. PubMed ID: 25028555
[TBL] [Abstract][Full Text] [Related]
57. Effects of ranolazine on cardiovascular system.
Bonadei I; Vizzardi E; Quinzani F; Piovanelli B; Rovetta R; D'Aloia A; Cas LD
Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):215-21. PubMed ID: 21867482
[TBL] [Abstract][Full Text] [Related]
58. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
59. Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Inglis S; Stewart S
Eur J Cardiovasc Nurs; 2006 Jun; 5(2):175-84. PubMed ID: 16469541
[TBL] [Abstract][Full Text] [Related]
60. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
Rosano GMC; Vitale C; Volterrani M
Cardiovasc Drugs Ther; 2016 Aug; 30(4):393-398. PubMed ID: 27417323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
